Sidi Yang

机构：Guangzhou Experimental Station, First Affiliated Hospital of Guangzhou Medical University, Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou Medical University · ORCID：0000-0003-0251-0162

发表论文 37 篇 · 总被引 497 次 · h-index 13

代表论文

• SARS-CoV-2 ORF3a sensitizes cells to ferroptosis via Keap1-NRF2 axis (2023 · Redox Biology · 被引 51)
• The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants (2022 · Science Translational Medicine · 被引 44)
• Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19 (2024 · Nature Communications · 被引 34)
• Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2 (2023 · Antiviral Research · 被引 19)
• Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1′-CN-4-aza-7,9-dideazaadenosine C-nucleoside (2023 · Signal Transduction and Targeted Therapy · 被引 14)
• Comparison of model‐specific histopathology in mouse models of COVID‐19 (2022 · Journal of Medical Virology · 被引 12)